Ontology highlight
ABSTRACT: Background
Immunotherapy using dendritic cell (DC) vaccine has the potential to overcome the bottleneck of cancer therapy.Methods
We engineered Lewis lung cancer cells (LLCs) and bone marrow-derived DCs to express tumor-associated antigen (TAA) ovalbumin (OVA) via lentiviral vector plasmid encoding OVA gene. We then tested the antitumor effect of modified DCs both in vitro and in vivo.Results
The results demonstrated that in vitro modified DCs could dramatically enhance T-cell proliferation (P<.01) and killing of LLCs than control groups (P<.05). Moreover, modified DCs could reduce tumor size and prolong the survival of LLC tumor-bearing mice than control groups (P<.01 and P<.01, respectively). Mechanistically, modified DCs demonstrated enhanced homing to T-cell-rich compartments and triggered more naive T cells to become cytotoxic T lymphocytes, which exhibited significant infiltration into the tumors. Interestingly, modified DCs also markedly reduced tumor cells harboring stem cell markers in mice (P<.05), suggesting the potential role on cancer stem-like cells.Conclusion
These findings suggested that DCs bioengineered with TAA could enhance antitumor effect and therefore represent a novel anticancer strategy that is worth further exploration.
SUBMITTER: Jiang T
PROVIDER: S-EPMC5266489 | biostudies-literature | 2017 Apr
REPOSITORIES: biostudies-literature
Jiang Tao T Chen Xiao X Zhou Wei W Fan Guoxin G Zhao Peilin P Ren Shengxiang S Zhou Caicun C Zhang Jun J
Translational oncology 20170125 2
<h4>Background</h4>Immunotherapy using dendritic cell (DC) vaccine has the potential to overcome the bottleneck of cancer therapy.<h4>Methods</h4>We engineered Lewis lung cancer cells (LLCs) and bone marrow-derived DCs to express tumor-associated antigen (TAA) ovalbumin (OVA) via lentiviral vector plasmid encoding OVA gene. We then tested the antitumor effect of modified DCs both in vitro and in vivo.<h4>Results</h4>The results demonstrated that in vitro modified DCs could dramatically enhance T ...[more]